Live news related to AB SCIENCE stock (FR0010557264): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The French biopharmaceutical group AB Science announced on the evening of January 7 a fourth consecutive clinical response observed with the combinati…
AB Science has reported the results of its phase 1 trial combining AB8939 and venetoclax in patients with refractory or relapsed acute myeloid leukemi…
AB Science announces that the United States Patent Office has issued a notice of allowance for a patent on the use of masitinib in the treatment of si…
AB Science announced on December 18 that Maxim Group, an American investment banking services firm, has initiated coverage of its stock with a buy rec…
AB Science announces the publication of a preclinical study on bioRxiv regarding AB8939, a new synthetic molecule developed to treat refractory acute …
AB Science has shared new results regarding masitinib, demonstrating clinical benefits in the treatment of amyotrophic lateral sclerosis (ALS), accord…
AB Science revealed preliminary results from Phase 1 of its treatment combining AB8939 and venetoclax for refractory or relapsed acute myeloid leukemi…
AB Science has announced the raising of a gross amount of 2.8 million euros in a private placement aimed at funding its clinical programs, particularl…
AB Science has released its financial results for the first half of 2025, revealing a 24% reduction in its operational deficit, but a 15.8% increase i…
